Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WRAIR Tetravalent Dengue Vaccine
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The WRAIR Tetravalent Dengue Vaccine (T-DEN) is a live-attenuated vaccine candidate developed by the Walter Reed Army Institute of Research (WRAIR) and the U.S. Army Medical Research and Development Command (USAMRDC). It is designed to provide protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine strains were attenuated through serial passage in primary dog kidney (PDK) cells. In specific clinical formulations, such as F17 and F19, Humulin R (regular human insulin) is added to the vaccine diluent as a stabilizer to prevent viral adsorption to the surfaces of vials and syringes. The vaccine is typically administered subcutaneously on a two-dose schedule (0 and 6 months) and aims to elicit a balanced neutralizing antibody response to prevent dengue fever and severe dengue disease.
- Other names
- Humulin R U-100-U.S. Army Medical Research and Development Command-dengueWRAIR Live Attenuated Tetravalent Dengue VaccineUSAMRDC Dengue Vaccine
02
Targets
DENV-3 E (Dengue virus serotype 3 envelope protein)Dengue virus serotype 1 envelope protein and associated virion structural antigensDENV-4 E (Dengue virus serotype 4 envelope protein)Dengue virus serotype 2 envelope protein
Beyond the preview
Go deeper on WRAIR Tetravalent Dengue Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WRAIR Tetravalent Dengue Vaccine.